Astellas Pharma (4503) Q2 2026 earnings summary

Executive summary

• Revenue and profits saw significant year-on-year growth, driven by strong performance of strategic brands such as PADCEV, IZERVAY, VEOZAH, VYLOY, and XTANDI, and effective cost optimization initiatives.

• Achieved exceptional Q2 YTD results, significantly outperforming expectations and prompting a major upward revision of full-year forecasts.

• Pipeline progress included successful clinical trials and regulatory milestones, notably for PADCEV, IZERVAY, and promising new data for ASP3082 and ASP2138.

• Full-year forecasts for revenue and operating profit were revised upward due to exceptional progress and robust sales momentum.

• Robust cost optimization through Sustainable Margin Transformation (SMT) initiatives delivered substantial savings.

Financial highlights

• Revenue reached ¥1,030.1 billion, up 10.1% year-on-year; underlying growth excluding forex impact was 12%.

• Core operating profit rose to ¥282.6 billion, up 54.4% year-on-year; margin increased by 7.9 percentage points to 27.4%.

• Operating profit surged 112.8% year-on-year to ¥199.4 billion; net profit doubled to ¥147.6 billion.

• Strategic brands revenue reached ¥220.5 billion, up 43% year-on-year, led by PADCEV and VYLOY.

• Free cash flow increased to ¥252.4 billion from ¥21.7 billion year-on-year.

Outlook and guidance

• Full-year revenue forecast revised upward by ¥100 billion to ¥2,030 billion, surpassing ¥2 trillion for the first time.

• Core operating profit forecast raised by ¥80 billion to ¥490 billion; operating profit also up by ¥80 billion to ¥240 billion.

• Core profit forecast increased to ¥365.0 billion (+20.1%), and basic core earnings per share to ¥203.79.

• Core operating profit margin expected at 24.1%, up 2.9 percentage points from initial forecast.

• Continued strong growth expected for strategic brands in the second half.